102 related articles for article (PubMed ID: 22020022)
1. The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD.
Chen X; Chang CH; Stein R; Goldenberg DM
Bone Marrow Transplant; 2012 Jul; 47(7):967-80. PubMed ID: 22020022
[TBL] [Abstract][Full Text] [Related]
2. Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response.
Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Fuchinoue S; Goldenberg DM; Kubota K
Am J Surg; 2012 Oct; 204(4):527-34. PubMed ID: 22658578
[TBL] [Abstract][Full Text] [Related]
3. Anti-human leukocyte antigen-DR (MHC class II) humanized monoclonal antibody, IMMU-114, suppresses human to bovine cellular responses.
Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Urakawa M; Aoyagi Y; Fuchinoue S; Kubota K
J Surg Res; 2012 Nov; 178(1):472-7. PubMed ID: 22487390
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death.
Setterblad N; Garban F; Weigl R; Assier E; Drillat P; Charron D; Dickinson A; Greinix H; Mooney N
Transfusion; 2008 Jan; 48(1):169-77. PubMed ID: 17900279
[TBL] [Abstract][Full Text] [Related]
6. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
7. Anti-HLA-DR-triggered monocytes mediate in vitro T cell anergy.
Kriegel MA; Adam-Klages S; Gabler C; Blank N; Schiller M; Scheidig C; Kalden JR; Lorenz HM
Int Immunol; 2008 Apr; 20(4):601-13. PubMed ID: 18310062
[TBL] [Abstract][Full Text] [Related]
8. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
Davies JK; Koh MB; Lowdell MW
Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
[TBL] [Abstract][Full Text] [Related]
9. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
Michálek J; Collins RH; Vitetta ES
Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
[TBL] [Abstract][Full Text] [Related]
10. The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model.
Fujioka T; Taniguchi Y; Masuda T; Nishida S; Ikegame K; Kawakami M; Tsuboi A; Hosen N; Murakami M; Oji Y; Oka Y; Sugiyama H; Kawase I; Ogawa H
Transpl Immunol; 2003; 11(2):187-95. PubMed ID: 12799203
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules.
van Els CA; Zantvoort E; Jacobs N; Bakker A; van Rood JJ; Goulmy E
Bone Marrow Transplant; 1990 Jun; 5(6):365-72. PubMed ID: 2142441
[TBL] [Abstract][Full Text] [Related]
12. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
Zeiser R; Marks R; Bertz H; Finke J
Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
14. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
15. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
16. Generation of self HLA-DR-specific CD3+CD4-CD8+ cytotoxic T cells in chronic graft-versus-host disease.
Yamamoto M; Sugihara K; Ohtsuki F; Tsujino Y; Tanaka A; Kamiya T; Wada H; Kanamaru A; Hara H; Yano A
Bone Marrow Transplant; 1994 Oct; 14(4):525-33. PubMed ID: 7858527
[TBL] [Abstract][Full Text] [Related]
17. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation.
Naderi N; Moazzeni SM; Pourfathollah AA; Alimoghaddam K
Transplant Proc; 2011 Dec; 43(10):3913-9. PubMed ID: 22172872
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of HLA-DR antigen expression in phytohemagglutinin-activated T cells in man. Requirement of T cell recognition of self HLA-DR antigen expressed on the surface of monocytes.
Moriya N; Sanjoh K; Yokoyama S; Hayashi T
J Immunol; 1987 Nov; 139(10):3281-6. PubMed ID: 3500214
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
